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The expression of telomerase in approximately 85% of cancers and its absence in the majority of normal
cells makes it an attractive target for cancer therapy. However the lag period between initiation of
telomerase inhibition and growth arrest makes direct inhibition alone an insufficient method of treat-
ment. However, telomerase inhibition has been shown to enhance cancer cell radiosensitivity. To
investigate the strategy of simultaneously inhibiting telomerase while delivering targeted radionuclide
therapy to cancer cells, 123I-radiolabeled inhibitors of telomerase were synthesized and their effects on
cancer cell survival studied. An 123I-labeled analogue of the telomerase inhibitor MST-312 inhibited
telomerase with an IC50 of 1.58 mM (MST-312 IC50: 0.23 mM). Clonogenic assays showed a dose dependant
effect of 123I-MST-312 on cell survival in a telomerase positive cell line, MDA-MB-435.
© 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Preclinical and clinical evidence supports the inhibition of
telomerase as a promising form of cancer therapy [1,2]. Telomerase
is present in the majority (85e90%) of cancers cell lines, and is
responsible for rescuing them from crisis, and promoting uncon-
trolled and continued tumor growth [1,3,4]. Telomerase inhibition
disrupts the replicative capacity of cancer cells by preventing
maintenance of the telomeric sequences at the chromosome ter-
minus, while leaving most normal somatic cells largely unaffected.
Telomerase activity is minimally reconstituted in vitro by
combining the human telomerase RNA template component (hTR)
[5] and the catalytic protein unit, human telomerase reverse tran-
scriptase (hTERT) [6].
The hTR template region provides an accessible substrate-
binding site allowing for direct enzyme inhibition using antisense
oligonucleotides, peptide nucleic acids (PNAs) and chemically
modified PNAs as competitive inhibitors, preventing active com-
plex formation with the hTERT component or binding to the telo-
mere substrate [7]. GRN163L (Imetelstat) is a lipid-conjugated N30-
P50 thio-phosphoramidate 13-mer oligonucleotide that has been
shown to inhibit telomerase and cause telomere shortening in cellsWaghorn), mark.jackson.2@
e.gouverneur@chem.ox.ac.uk
K.A. Vallis).
r Masson SAS. This is an open accefrom brain, bladder, liver, lung, prostate and stomach cancers
[8e14].
Although hTR is expressed ubiquitously, telomerase activity is
restricted by the expression of the hTERT component [15,16].
Numerous small molecule inhibitors of telomerase have been
identified [17e20]. Most notably BIBR-1532 [21,22], where dose-
dependent inhibition of telomerase with increasing concentra-
tions of BIBR-1532 has been shown, without significant effects on
normal cells [23]. Other inhibitors include azidothymidine [24,25],
the epicatechin derivatives, EGCG and MST-312 that strongly and
directly inhibit telomerase [26e28], isothiazolone and bis-indole
derivatives [29,30], and several G-quadruplex stabilizing mole-
cules [31e33].
Several clinical trials are currently underway, targeting both the
telomeres and telomerase function. Clinical trials with Imetelstat
for haematological malignancies (essential thrombocythemia (ET),
myelodysplastic syndrome, acute myelogenous leukaemia) and
myelofibrosis (MF) are planned, underway or completed [34]. So far
phase II trials for ET and MF have found no correlation between
clinical response and telomere length [35]. Currently phase I/II
clinical trials with the oncolytic virus, OBP-301, are underway in
patients with hepatocellular carcinoma. In phase I testing OBP-301
was well tolerated with no serious adverse effects [36]. The cancer
vaccine, GV1001, a TERT derived peptide for telomerase driven
immunotherapy is involved in several clinical trials in non-small
cell lung cancer (NSCLC), pancreatic cancer, hepatocellular carci-
noma and malignant melanoma, where few side effects have been
reported [37]. In phase I/II NSCLC studies a GV1001-specificss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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pancreatic cancer, however, no improvement in overall survival
was observed [39]. Although BIBR-1532, MST-312 and several G-
quadruplex inhibitors have had success in preclinical testing they
have not yet entered into clinical trials. The G-quadruplex stabilizer
Quarfloxin/CX-3543 has entered phase I and II trials but is thought
to induce apoptosis through inhibition of ribosomal RNA (rRNA)
[40]. Several tankyrase inhibitors such as XAV939, which disrupt
telomere length regulation are being tested as treatment strategies
but have not yet entered clinical trials [41]. Despite significant in-
sights into the role of telomerase in disease there is still no agent
yet approved for clinical use [42].
The relationship between cellular radiosensitivity and telomere
length is one that has been investigated extensively [43e47].
Goytisolo et al. reported the connection between shortenened
telomeres in late generation mTR/mice and radiation response,
evident as organism hypersensitivity to IR and increased DNA
damage after irradiation [48]. SimilarlyWong et al. have shown that
telomerase inhibition and telomere dysfunction in fibroblasts from
late generation Terc/mice imparts an enhanced radiosensitivity
associated with increased mortality [49e51]. Similar studies have
shown enhanced radiosensitivity in mice where telomeres have
been shortened by mutant hTERT expression [44,45,52,53].
Increased telomerase expression has been associated with
enhanced genome stability and DNA repair mechanisms, providing
a protective mechanism against DNA damage [54,55].
Radiolabeled agents that specifically inhibit telomerase activity
would be expected, therefore, to selectively increase radiosensi-
tivity and so increase tumor cell kill [56]. We report here the syn-
thesis of a series of small molecule telomerase inhibitors, the
protocols for radiolabeling them with the Auger electron-emitting
isotope, 123I, and their effect on telomerase inhibition and cancer
cell survival.
2. Results and discussion
The telomerase inhibitory capabilities of BIBR-1532, MST-312
and the flavonoid species 2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-
4H-chromen-4-one (Fig. 1) have been directly compared under the
same experimental conditions obtaining IC50 values of 3.6, 12.1 and
0.23 mM, respectively [57]. Structure activity relationship studies
with the BIBR-1532 and flavonoid species have shown that certain
site specific structural modifications to these parent structures have
only minimal effects on telomerase inhibition, suggesting inclusionFig. 1. Structures of telomerase inhibitors; BIBR-1532, Flavonoof an Iodine-123 radiolabel modification to allow for combined
targeted therapy would have limited effect on telomerase inhibi-
tion in these species. As well as decaying by release of high energy,
short pathlength Auger electrons, 123I was selected for site-specific
inclusion in these molecules to minimize the structural alterations
that would be encountered with metal radioisotopes.
2.1. Chemistry
In Fig. 1 the chemical structures of the iodinated analogues and
their parent precursors, tested for in vitro telomerase inhibition, are
reported. Schemes 1e3 show the synthetic pathways employed in
the preparation of the iodinated derivatives 1e6. The iodinated
BIBR-1532 analogues (Scheme 1) were prepared using an adapted
literature protocol [58]. Briefly, the condensation reaction of the
acid chloride of (E)-3-(naphthalen-2-yl)but-2-enoic acid with
either the commercially available 5-iodo-2-aminobenzoate or with
4-iodo-2- aminobenzoate prepared from N-(4-iodo-2-methyl-
phenyl)-acetamide in 2 steps gave 1b and 2b in 72% and 67% yield
respectively.
Base hydrolysis of 1b and 2b gave 1 and 2 in 93% and 95% yield
respectively. The trimethyltin analogue was prepared by reaction of
1b with hexamethyldistannane and bis-(triphenylphosphine)-pal-
ladium(II)-dichloride in 1,4-dioxane to afford 1c after column
chromatography. Base hydrolysis of 1c gave 1d in 87% yield.
The iodinated flavonoids (Scheme 2) were prepared using the
Baker-Venkataraman transformation following an adapted litera-
ture protocol. An appropriate hydroxyacetophenone was reacted
with an appropriate analogue of 3,4-dimethoxybenzoyl chloride to
yield a benzoyl ester that, after treatment with base, yields a 1,3-
diketone. Treatment of the diketone in acid affords the protected
flavone and demethylation achieved using 1 M boron tribromide in
dichloromethane at 0 C yields the flavone product. In the case of 3,
iodinated hydroxyacetophenone 3a was prepared by reaction of
2,3-dimethoxy-2-hydroxyacetophenone with N-iodosuccinimide
and p-toluenesulphonic acid in acetonitrile [59].
3a was subsequently reacted with the commercially available
3,4-dimethoxybenzoyl chloride to give 3b which was converted to
the 1,3-diketone, 3c. Cyclodehydration was achieved in acetic acid
to give 3d and demethylation gave 3. For 4 and 5, 3,4-dimethoxy-2-
hydroxyacetophenone was reacted with the acid chloride of either
the commercially available 2-iodo-4,5-dimethoxybenzoic acid to
give 4b or with 3-iodo-4,5- dimethoxybenzoic acid prepared from
3-iodo-4-hydroxy-5-methoxybenzaldehyde in 2 steps to give theid (FLAV) and MST-312, and iodinated derivatives (1e6).
Scheme 1. i) a) oxalyl chloride, DMF, DCM, 5 h 0 C, b) 1a/2a, pyridine, DMAP, THF, 2 h, r.t.; ii) LiOH, THF, H2O, 12 h, r.t.; iii) Sn2Me6, PdCl2(PPh3)2, 1,4-dioxane, 2 h, 60 C; iv) LiOH,
THF, H2O, 12 h, r.t.; v) [123I]NaI, Chloramine T, MeCN, 15 min, r.t.
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The trimethyltin analogue of 3 was prepared by first synthe-
sizing the acetyl protected analogue by reaction of 3 with acetic
anhydride in pyridine. Then 3gwas prepared by reaction of 3fwith
hexamethylditin and bis-(triphenylphosphine)-palladium(II)-
dichloride to give 3g in 58% yield. 4g and 5g were prepared in
identical fashion.
The iodinated MST-312 analogue 6 (Scheme 3) was prepared by
the condensation of 6a with the acid chloride of 6b, followed by
demethylation with boron tribromide. The stannane analogue was
prepared by the condensation of 6a with the acid chloride of 6d,
followed by reaction with hexamethylditin and bis-(triphenyl-
phosphine)-palladium(II)-dichloride to give 6f in 26% yield.
2.2. Telomerase inhibition
Telomerase Repeat Amplification Protocol (TRAP) measure-
ments have demonstrated that the iodinated compounds were able
to directly inhibit telomerase activity in a cell free system with
minimally reduced inhibitory potencies compared to their respec-
tive parent compounds as a result of inclusion of the iodide sub-
stituent. Compounds 1 and 2 were shown to have IC50 values of
30.09 mM and 28.08 mM respectively, corresponding to a ~2.5 fold
reduction in telomerase inhibitory activity with respect to the
parent BIBR-1532 compound (IC50: 11.57 mM). The iodinated
flavonoid isomers 3 and 5 displayed telomerase inhibitory capa-
bilities with IC50 values of 1.65 and 1.73 mM respectively, similarly
corresponding to a 2.0e2.2 fold reduction in telomerase inhibitory
activity with respect to the parent flavonoid compound (IC50:
0.74 mM). The IC50 values measured for BIBR-1532 and the parent
flavonoid, 7,8,30,40-tetrahydroxyflavone, differ from those previ-
ously reported in the literature, which we ascribe to variations inmethod and the cell line that was used. Compound 4was found not
to inhibit telomerase activity to the same extent as 3 and 5 (See
Supporting Information) and as such further radiolabeling studies
with 4 were not conducted. Compound 6 displayed no telomerase
inhibitory activity under the described protocol, however under
these experimental conditions the parent MST-312 compound
similarly failed to inhibit telomerase in the TRAP setup that was
used in this study. TRAP experiments were repeated with com-
pound 6 and parent MST-312 compound using a range of alterna-
tive telomerase positive cell lysates but no positive inhibition with
MST-312 was observed, suggesting that direct inhibition of telo-
merase is not the method of inhibition in these cell lines. Indirect
effects such as signaling or changes in expression levels, or the need
of metabolic activation of MST-312 in cells may be required for
telomerase inhibition. To address this, cells were plated in six well
plates and treated with different concentrations of either parent
MST-312 or 6 over a 24 h incubation period. Cell lysates for each
treated sample were prepared as described in the Supporting In-
formation and the TRAP assay performed on the individually pre-
pared lysate samples. Results indicate a concentration dependent
inhibition of telomerase activity after in vitro treatment of whole
cells with the MST compounds, with the iodinated species 6 having
an IC50 of 1.58 mM compared with 0.23 mM for the parent MST-312
compound. In all cases the inclusion of an iodide substituent led to
only a slight reduction in IC50 values, maintaining the possibility for
potential telomerase inhibition and targeting (Table 1).
The lag period required after telomerase inhibition to observe
critical telomere shortening and cell crisis suggests that telomerase
inhibition alonemay be insufficient as a stand-alone treatment. The
presence of components of the DNA damage response pathways at
the telomeres together with a reported telomere-independent role
for telomerase in DNA repair suggests that a combination of
Scheme 2. i) 3,4-dimethoxybenzoyl chloride, pyridine, 2 h, r.t.; ii) a) oxalyl chloride, DMF, DCM, 2 h 0 C, b) 3,4-dimethoxy-2-hydroxyacetophenone, pyridine, DCM, 2 h, r.t.; iii)
KOH, pyridine, 1 h, 50 C; iv) NaOAc, AcOH, 2 h, 120 C; v) Sn2Me6, PdCl2(PPh3)2, 1,4-dioxane, 1.5 h, 60 C; vi) BBr3, DCM, 2 h, 0 C e r.t.; vii) Ac2O, pyridine, 20 h, 45 C; viii) Sn2Me6,
PdCl2(PPh3)2, 1,4-dioxane, 1.5 h, 60 C.
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potentially interacting [60]. We therefore prepared the radio-
labelled analogues of the iodinated inhibitors to investigate further
the effect of a combined radiotherapeutic with telomerase
inhibition.
2.3. Radioiodination
To regioselectively prepare radioiodinated agents trimethyltin
precursors were first prepared. In the case of the BIBR-1532 de-
rivative the trimethyltin complex 1d could not be isolated as a pure
species by direct stannylation of the iodinated analogue, (1).
Instead the trimethyltin complex of 1b was prepared which was
stable to column chromatography on neutral silica and 1d prepared
subsequently by basic hydrolysis of 1c, following workup withcareful control of pH to avoid proto-destannylation. [123I]-(1) was
subsequently radiolabeled using Chloramine T (N-chloro-p-tolue-
nesulfonamide sodium salt) as an oxidant with a decay corrected
isolated end of synthesis yield of 76% ± 6% (n ¼ 10) and a radio-
chemical purity as assessed by analytical radio-HPLC of >97%, with
a specific activity of 6.08 ± 0.28 Ci/mmol (Fig. 2a). Attempts to
prepare a trimethyltin derivative directly from the parent com-
pound, 3, met with poor yields and difficulties in purification.
Accordingly a trimethyltin analogue 3e was prepared from the
methoxy protected precursors necessitating the inclusion of a
subsequent deprotection step following successful radiolabeling.
Although radiolabeling was possible in good yields (72%), subse-
quent deprotection attempts of the four methoxy groups using HI
or BBr3 as per the cold synthesis, met with limited success resulting
in low yields and with multiple side products seen by radio-HPLC
Scheme 3. i) a) 6b, oxalyl chloride, DMF, DCM, 2 h 0 C, b) 6a, pyridine, DCM, 2 h, r.t.; ii) BBr3, DCM, 2 h, 0 C e r.t.; iii) a) 6d, oxalyl chloride, DMF, DCM, 2 h 0 C; b) 6a, pyridine,
DCM, 2 h, r.t.; iv) Sn2Me6, PdCl2(PPh3)2, 1,4-dioxane, 12 h, 75 C; v) [123I]NaI, H2O2:HOAc, MeCN, 15 min, r.t.; vi) 3 M HCl, MeOH, 0.5 h, 80 C.
Table 1
Telomerase inhibition data for compounds 1-6.
Compound IC50 (mM)
BIBR-1532 11.57
1 30.09
2 28.08
Flavonoid 0.74
3 1.65
4 N/D
5 1.73
MST-312 0.23
6 1.58
N/D: Not determined.
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strategies were sought and the acetylated analogue, 3g, was pre-
pared accordingly. Again the initial radiolabeling step was per-
formed in good to high yields, and following treatment with 3 M
HCl at elevated temperatures deprotection of the four acetyl groups
was achieved in good yield. Attempts to deprotect the acetyl groups
under basic conditions led to complete deiodination of the flavo-
noid species. [123I]-(3) was radiolabeled in a yield of 86 ± 8%
(n ¼ 10) and following deprotection was prepared with a decay
corrected end of synthesis yield of 64 ± 4% (n ¼ 10) and with a
radiochemical purity as assessed by analytical radio-HPLC of >98%,with a specific activity of 2.60 ± 0.17 Ci/mmol (Fig. 2b).
[123I]-(5) was labeled in a similar fashion with an end of syn-
thesis yield of 67% ± 6% (n ¼ 10) and with a radiochemical purity of
>98%. The trimethyltin derivative, 6f was prepared in similar
fashion to the flavonoid species. A range of oxidants was explored
and labeling optimized with hydrogen peroxide in acetic acid giv-
ing a radiolabeling yield of 55 ± 3% (n ¼ 6). Following deprotection
and subsequent HPLC and Seppak cartridge purification steps a
decay corrected end of synthesis yield of 22 ± 5% was obtained,
with a radiochemical purity >97%, and a specific activity of
2.89 ± 0.24 Ci/mmol.
The lipophilicity of compounds can affect their tissue perme-
ability properties, which can impact their localization in target
tissues. Lipophilicity may also affect binding to low affinity
nonspecific sites that can compromise target tissue to background
tissue ratios. The octanol/water and octanol/PBS partition co-
efficients were measured using a standard protocol. [123I]-(1) dis-
played a Log P: 1.84 ± 0.06 and Log D: 1.57 ± 0.14, indicative of a
lipophillic species possessing aromatic functionality as for the
naphthyl group present. [123I]-(3) and [123I]-(5) were more polar
with Log P: 1.14 ± 0.07 and Log D: 0.99 ± 0.06, and Log P: 1.18 ± 0.08
and Log D: 0.98 ± 0.07 respectively. [123I]-(6) displays a Log P:
1.57 ± 0.11 and Log D: 1.23 ± 0.21.
In vitro stability experiments were conducted in PBS, and in
serum complete medium (10% FBS). At regular intervals over a 24 h
Fig. 2. Radiotrace and UVtrace for a) [123I]-(1), b) [123I]-(3) and c) [123I]-(6).
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Incubation of [123I]-(1) and [123I]-(6) gave a single peak by radio-
HPLC at all time points with an integrated area of >98% and a
retention time that correlated with 1 and 6 respectively. No signs of
deiodination or decomposition were observed in PBS buffer. In
contrast, HPLC analysis of [123I]-(3) showed signs of complex
decomposition with a loss of radio-iodide label within 4 h incu-
bation in PBS. After 24 h in PBS, only 48% of intact compound
remained. The only peaks in the radiotrace corresponded to intact
complex and a peak with the same retention time as free iodide,
suggesting direct loss of iodide, possibly as a result of a radical
anion pathway mediated by the oxidation of the flavonoid species
in solution to give reactive radical intermediates [61,62]. The
instability of [123I]-(3) and [123I]-(5) over extended incubation pe-
riods rendered these compounds unsuitable for further in vitrodevelopment. Similar complex instability was seen for [123I]-(5) in
PBS, with only 53% intact compound remaining after 24 h respec-
tively. In keeping with their lipophillic nature both 1 and 6 after
incubation in serum containing medium, remained localized to the
protein pellet after protein precipitation. Sephadex size exclusion
separation of the solutions reinforced that all activity was associ-
ated with large protein biomolecules, with the radioactive fraction
eluting in early solvent volumes. Free iodide controls eluted later
suggesting that there is no loss of free iodide after 24 h incubation
of 1 or 6 in serum containing medium.
2.4. In vitro evaluation
Cell uptake studies were performed in the MDA-MB-435 mel-
anoma cell line as a telomerase expressing cell line. Internalization
studies with [123I]-(1) showed limited cell uptake, with <0.1% of the
radiolabeled drug internalized over a 24 h incubation period,
despite favorable partition coefficient data. Repeat internalization
studies with alternative cancer cell lines including MDA-231/H2N
breast and U2OS osteosarcoma cancer cell lines all showed low
cell uptake. No loss in survival was subsequently seen on incuba-
tion with the MDA-MB-435 cell line as determined by colony for-
mation, and as such attention was focused thereafter on [123I]-(3)
and the iodinated MST-312 compound.
After 24 h incubation, the iodinated MST-312 compound, [123I]-
(6), displayed uptake in MDA-MB-435 cells, with 15% of the total
incubated activity being cell-associated after 24 h, of which 60%
was shown to be localized within the nucleus.
The effects of combined irradiation with telomerase inhibition
have so far only been investigated using external beam sources. To
date no approach has pursued the use of intrinsically targeted small
molecule radiotherapeutics to study if radiosensitization effects can
be achieved, by retention of a radioactive probe in cancer cells that
over-express telomerase. Localization of a radionuclide in prox-
imity to the enzyme active-site may further enhance catalytic in-
hibition, following radiolytic disruption. Binding to the active-site
of this intranuclear enzyme is also likely to promote the retention
of small molecule inhibitors in the nuclei (of cancer cells), poten-
tiating effects mediated via radioactive decay. Given the nuclear
uptake and telomerase inhibition of 6, clonogenic studies were
performed with increasing radioactivity concentrations of the
radiolabeled [123I]-(6) species. Concentrations between 0 and
20 MBq/mL were incubated with the MDA-MB-435 cell line for
either 4 or 24 h before being plated out at a concentration of
1000 cells/mL in DME medium and left to form colonies over a 10
day period. Reduced survival with increasing concentration of
radiolabeled drug was observed, with lower surviving fraction (SF)
after incubation for 24 h (Fig. 3a). Control clonogenic assays with
MST-312 and non-radioactive 6 run in parallel show that for the
radiolabeled species even at the highest radioactivity concentra-
tions used (20 MBq/mL), the concentration of compound present
(0.18 mM, based on specific activity measurements) was not suffi-
cient to illicit a significant clonogenic effect (survival fraction: 0.97).
As such the low SF observed is as a direct result of a response to
radiation-induced cell damage (Fig. 3b).
For comparison with a telomerase negative cell line, the U2OS
osteosarcoma cell line was studied in parallel to the MDA-MB-
435 cell line (Fig. 3). Comparable uptake and retention to the MDA-
MB-435 cell line was seen in the U2OS cell line. Clonogenic studies
(n ¼ 8) in U2OS and MDA-MB-435 cells lines run in parallel show
that although at the highest activity-concentrations comparable
loss in survival is observed for both cell lines (SF at 20MBq/mL; 0.11
vs 0.11 for MDA-MB-435 vs U2OS, P ¼ 0.76), at lower activity
concentrations the SF for the MDA-MB-435 cell line is lower than
that for U2OS (SF at 5 MBq/mL: 0.55 vs 0.72 for MDA-MB-435 vs
Fig. 3. a) Clonogenic survival data for MDA-MB-435 and U2OS cell lines after 24 h
treatment with increasing activity concentrations of [123I]-(6); b) Clonogenic survival
data for MDA-MB-435 cell line after 24 h treatment with increasing activity concen-
trations of (6) or MST-312.
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U2OS, P ¼ 0.001), which it is hypothesised may result from the
presence of telomerase facilitating nuclear retention of the iodin-
ated MST-312 species.
Cell studies with [123I]-(3) in the MDA-MB-435 cell line showed
uptake of 2.9% of the total activity to be cell associated after 24 h.
Clonogenic studies between 0 and 16 MBq/mL of [123I]-(3) with
MDA-MB-435 cell line for 24 h showed statistically significantly
reduced survival with increasing concentration of radiolabelled
drug compared to free iodide alone (Fig. 4). Cell survival wasFig. 4. Clonogenic survival data for MDA-MB-435 cell line after 24 h treatment with
increasing activity concentrations of [123I]-(3) or Na123I.reduced to 36 ± 2% following incubation with 16 MBq/mL of [123I]-
(3), compared to 84 ± 4% with the Na123I control, suggesting that
the combination of telomerase inhibition and irradiation is cyto-
toxic. However, given the instability of [123I]-(3) (and [123I]-(5))
over extended incubation periods such class of compounds were
deemed not suitable for further development.
Excluding the germ line, telomerase expression in stem-cell
compartments is rarely sufficient to maintain telomere length,
with shortening observed with increasing age [63]. Though anti-
telomerase therapy could possibly affect stem cells of renewal tis-
sues (such as crypt cells of the intestine, basal cells of the skin, and
certain hematopoietic cells of the blood) [64], the telomeres of such
cells are generally much longer than cancer cell telomeres
[5,65e67]. This differential telomerase expression in cancer versus
stem cells provides a means to deliver the telomerase-targeting
radiotherapeutic [123I]-(6) to neoplastic cells, with minimal dam-
age to normal stem-cell populations.
3. Conclusion
To investigate the possible use of telomerase as a target for
molecularly targeted radiotherapy, we synthesized and character-
ized a panel of radioiodinated analogues of three known telome-
rase inhibitors: BIBR-1532, a flavonoid (2-(3,4-dihydroxyphenyl)-
7,8-dihydroxy-4H-chromen-4-one) and MST-312. The radio-
iodinated derivatives all retained telomerase inhibitory capacity
either in cell-free (lysate) or in whole cell experiments. 123I-BIBR-
1532 internalized into cancer cells to only a modest extent. 123I-
labeled flavonoid was markedly cytotoxic in clonogenic assays but
was moderately unstable in serum. 123I-MST-312, however, showed
uptake in two cancer cell lines, was stable and elicited radioactivity
concentration-dependent cancer cell death. The reduction in cell
survival was greater in a telomerase positive versus telomerase
negative cell line. Further studies will look at a greater range of
telomerase positive and negative cell lines to establish the broad
applicability of (6) as a targeted radiotherapy agent against
telomerase-positive cancers.
4. Experimental section
4.1. General methods
All reactions were carried out in oven-dried glassware under a
nitrogen atmosphere. Nitrogen gas was dried by passage through
silica gel. All solvents were dried according to standard procedures.
All reagents were purchased from Aldrich and used without further
purification. Column chromatography was performed on silica gel
60 M (mesh 230e400) Macherey-Nagel. 1H and 13C NMR spectra
were recorded on a Bruker DPX400 (400 MHz) spectrometer or
Bruker AVC500 (500MHz) spectrometer at 298 K and referenced to
residual non-deuterated solvent peaks. Mass spectrometry was
performed using a Bruker Micromass LCT time-of-flight mass
spectrometer under conditions of electrospray ionization (ESI-MS).
Accurate masses are reported to four decimal places using tet-
raoctylammonium bromide (466.5352 Da) as an internal reference.
HPLC characterization (analytical HPLC) of compounds was per-
formed using a Waters C-18 column (4.6  250 mm) with UV/Vis
detection at lobs ¼ 254 nm with a 1.0 mL/min gradient elution
method; Method A (Solvent A: acetonitrile with 0.1% TFA v/v, Sol-
vent B: water with 0.1% TFA v/v): start 50% A, gradient over 7 min
reaching 80% A, then gradient until 13 min reaching 95% A, reverse
gradient till 14 min reaching 50% A, then hold to 15 min at 50% A,
Method B (Solvent A: acetonitrile with 0.1% TFA v/v, Solvent B:
water with 0.1% TFA v/v): start 5% A, gradient over 15 min reaching
95% A, hold to 16 min at 95% A, reverse gradient till 18 min reaching
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Elemental analyses were performed by Mr. S. Boyer, at London
Metropolitan University.
No-carrier added radiochemical sodium iodide I-123 was sup-
plied by GE Healthcare. Radio-HPLC was carried out under identical
conditions to analytical HPLC, on an Agilent 1200 series module
equipped with a LabLogic Gamma-Ram-4 radiodetector.
Compounds (E)-3-(naphthalen-2-yl)but-2-enoic acid [68], 4-
iodo-2-aminobenzoate [69], 3-Iodo-4,5-dimethoxybenzoic acid
[70] and 1-iodo-3,5-diaminobenzene [71] were prepared as pre-
viously described. All data was in accord with literature values. Full
experimental data and spectra for all compounds prepared in this
work may be found in the Supporting Information.
4.1.1. I-BIBR-1532 compound data
4.1.1.1. (E)-Methyl 5-iodo-2-(3-(naphthalen-2-yl)but-2-enamido)
benzoate (1b). (E)-3-(Naphthalen-2-yl)but-2-enoic acid (1.00 g,
4.71 mmol) was suspended in dry dichloromethane (15 mL) in a
flame dried flask under an argon atmosphere and cooled to 0 C.
Oxalyl chloride (0.848 g, 0.447 mL, 9.42 mmol) and a catalytic
amount of DMF (2 drops) was added to the suspension and allowed
to warm to room temperature. The solution was stirred at room
temperature for 5 h after which all volatiles were removed under
reduced pressure. The crude product was redissolved in dry
dichloromethane (15 mL) and solvent removed under reduced
pressure three times before drying under high vac. The crude
product was redissolved in dry THF (20 mL) in a flame-dried flask
under an argon atmosphere. To this was added 5-iodo-2-
aminobenzoate (1.86 g, 7.07 mmol), pyridine (1.12 g, 1.14 mL,
14.1 mmol) and a catalytic amount of DMAP (0.01 g, 0.082 mmol).
After stirring at 60 C for 16 h, the reaction was allowed to cool to
room temperature, poured onto 1 N HCl and extracted into diethyl
ether. The combined organic layers were dried over anhydrous
magnesium sulphate and concentrated under vacuum to give the
crude product. Purification by flash chromatography (8% methanol
in dichloromethane) afforded the analytically pure product. (Yield:
1.60 g, 3.39 mmol, 72%). 1H NMR (CDCl3, 500 MHz, 20 C): d ¼ 11.18
(s, 1H, NH), 8.70 (d, J¼ 9.1 Hz, 1H, ArH), 8.36 (d, J ¼ 2.2 Hz, 1H, ArH),
7.98 (d, J ¼ 1.3 Hz, 1H, NpH), 7.89 (m, 3H, ArH þ NpH), 7.83 (d,
J ¼ 2.2 Hz, 1H, NpH), 7.64 (dd, J ¼ 8.5, 1.9 Hz, 1H, NpH), 7.53 (m, 2H,
NpH), 6.37 (q, J ¼ 0.9 Hz, 1H, COCH), 3.95 (s, 3H, COOCH3), 2.77 (d,
J ¼ 1.0 Hz, 3H, CCH3). 13C NMR (CDCl3, 125 MHz, 20 C): d ¼ 167.6,
165.3,154.0,143.1,141.7,139.6,139.3,133.4,133.1,128.5,128.2,127.6,
126.6, 126.5, 125.8, 124.0, 122.2, 120.8, 116.5, 84.7, 52.6, 18.0. ESMS
calcd for C22H18INNaO3 [MþNa]þ: 494.0224, found 494.0221. HPLC
(method A): Rt ¼ 14.14 min.
4.1.1.2. (E)-5-Iodo-2-(3-(naphthalen-2-yl)but-2-enamido)benzoic
acid (1). LiOH (27.8 mg, 0.663mmol,1 M aq. solution) was added to
a solution of (E)-methyl 5-iodo-2-(3-(naphthalen-2-yl)but-2-
enamido)benzoate (0.250 g, 0.530 mmol) in THF/H2O (5:1, 10 mL)
and stirred at room temperature. After 12 h, the reaction was
acidified to pH 4 using 1 M aq. oxalic acid solution and extracted
with ethyl acetate. The combined organic layers were dried over
anhydrous magnesium sulphate and concentrated under vacuum
to give the final product. (Yield: 0.226 g, 0.493 mmol, 93%). 1H NMR
(d6-DMSO, 500 MHz, 20 C): d ¼ 13.87 (br s, 1H, COOH), 11.16 (s, 1H,
NH), 8.38 (d, J ¼ 8.8 Hz, 1H, ArH), 8.23 (d, J ¼ 2.2 Hz, 1H, ArH), 8.14
(d, J¼ 1.3 Hz, 1H, NpH), 7.99 (m,1H, NpH), 7.92 (m, 3H, ArHþ NpH),
7.75 (dd, J ¼ 8.8, 1.9 Hz, 1H, NpH), 7.54 (m, 2H, NpH), 6.51 (d,
J ¼ 0.9 Hz, 1H, COCH), 2.66 (d, J ¼ 1.1 Hz, 3H, CCH3). 13C NMR (d6-
DMSO, 125 MHz, 20 C): d ¼ 168.0, 164.5, 151.7, 142.0, 140.4, 139.0,
138.8, 133.0, 132.8, 128.5, 128.1, 127.4, 126.8, 126.6, 125.7, 123.9,
122.5, 120.8, 119.2, 85.9, 17.2. ESMS calcd for C21H16INNaO3
[MþNa]þ: 480.0067, found 480.0071. HPLC (method A):Rt ¼ 9.89 min. Elemental analysis for C21H16INO3, calc: C 55.2%, H
3.5%, N 3.1%, found: C 55.3%, H 3.6%, N 2.9%.
4.1.1.3. Methyl (E)-2-(3-(naphthalen-2-yl)but-2-enamido)-5-(trime-
thylstannyl)benzoate (1c). To a solution of (E)-methyl 5-iodo-2-(3-
(naphthalen-2-yl)but-2-enamido)benzoate (0.100 g, 0.212 mmol)
in degassed anhydrous 1,4-dioxane (5.00 mL) was added hexame-
thyldistannane (0.167 g, 106 mL, 0.509 mmol) and bis-(triphenyl-
phosphine)-palladium(II)-dichloride (1.50 mg, 2.17 mmol), and the
solution stirred at 60 C for 1.5 h under argon. The solution was
cooled to room temperature and filtered through a plug of celite
with dichloromethane washing. The solvent was removed in vacuo
and purification by flash chromatography on neutral silica (2%
methanol in dichloromethane) afforded the analytically pure
product as awhite solid. (Yield: 69.0 mg, 0.136mmol, 64%). 1H NMR
(CD2Cl2, 500 MHz, 20 C): d ¼ 11.20 (s, 1H, H9), 8.81 (d, J ¼ 8.2 Hz,
1H, H7), 8.18 (d, J ¼ 1.2 Hz (84%), with Sn satellites (J2Sn-H ¼ 47 and
44 Hz (16%)), 1H, H4), 8.01 (d, J¼ 1.6 Hz,1H, H15), 7.84e7.95 (m, 3H,
H17 þ 20þ22), 7.71 (dd, J ¼ 8.1, 1.3 Hz (84%), with Sn satellites (J2Sn-
H ¼ 48 Hz (16%)), 1H, H6), 7.68 (dd, J¼ 8.8, 1.8 Hz, 1H, H23), 7.53 (m,
2H, H18 þ 19), 6.41 (d, J ¼ 1.3 Hz, 1H, H11), 3.93 (s, 3H, H1), 2.75 (d,
J¼ 1.3 Hz, 3H, H13), 0.34 (s (84%), with Sn satellites (J2Sn-H¼ 54 and
56 Hz (16%)), 9H, Sn(CH3)3). 13C NMR (CD2Cl2, 125 MHz, 20 C):
d ¼ 169.6, 165.7, 153.2, 142.5, 142.4, 140.3, 138.6, 136.2, 134.0, 133.8,
129.0, 128.6, 128.1, 127.1, 127.0, 126.3, 124.6, 121.8, 120.0, 115.2, 52.8,
18.1, 9.2 (with Sn satellites; 7.8, 7.9, 10.6, 10.7), Sn(CH3)3.
ESMS calcd for C25H27NNaO3Sn [MþNa]þ: 532.0910, found
532.0899. HPLC (method B): Rt ¼ 14.24 min.
4.1.1.4. (E)-2-(3-(Naphthalen-2-yl)but-2-enamido)-5-(trimethyl-
stannyl)benzoic acid (1d). LiOH (4.71 mg, 0.197 mmol, 1 M aq. so-
lution) was added to a solution of (E)-2-(3-(naphthalen-2-yl)but-2-
enamido)-5-(trimethylstannyl)benzoate (0.050 g, 0.098 mmol) in
THF/H2O (5:1, 10 mL) and stirred at room temperature. After 12 h,
the reaction was acidified to pH 4 using 1 M aq. oxalic acid solution
and extracted with ethyl acetate. The combined organic layers were
dried over anhydrous magnesium sulphate and concentrated under
vacuum to give the final product. (Yield: 42.3 mg, 0.086 mmol,
87%). 1H NMR (d6-DMSO, 500 MHz, 20 C): d ¼ 13.52 (br s, 1H, H1),
11.21 (s, 1H, H9), 8.51 (d, J ¼ 8.2 Hz, 1H, H7), 8.11 (d, J ¼ 1.4 Hz, 1H,
H15), 8.08 (d, J ¼ 1.2 Hz (84%), with Sn satellites (J2Sn-H ¼ 46 and
43 Hz (16%)), 1H, H4), 7.92e8.02 (m, 3H, H17 þ 20þ22), 7.79 (dd,
J ¼ 8.7, 1.6 Hz, 1H, H23), 7.72 (dd, J ¼ 8.2, 1.3 Hz (84%), with Sn
satellites (J2Sn-H ¼ 47 and 44 Hz (16%)), 1H, H6), 7.56 (m, 2H,
H18 þ 19), 6.53 (d, J ¼ 1.2 Hz, 1H, H11), 2.67 (d, J ¼ 0.7 Hz, 3H, H13),
0.31 (s (84%), with Sn satellites (J2Sn-H ¼ 53 and 56 Hz (16%)), 9H,
Sn(CH3)3). 13C NMR (d6-DMSO, 125 MHz, 20 C): d ¼ 170.1, 164.4,
150.6, 140.8, 140.7, 138.9, 138.8, 133.0, 132.8, 131.5, 128.4, 128.1,
127.5, 126.7,126.6,125.6,124.0, 122.4,121.4, 119.4, 17.3, -9.3 (with Sn
satellites; 7.6, 7.7, 10.4, 10.5), Sn(CH3)3. ESMS calcd for
C24H25NNaO3Sn [MþNa]þ: 518.0753, found 518.0744. HPLC
(method B): Rt ¼ 11.97 min. Elemental analysis for C24H25NO3Sn,
calc: C 58.3%, H 5.1%, N 2.8%, found: C 57.9%, H 5.2%, N 2.9%.
4.1.2. I-FLAV compound data
4.1.2.1. 1-(5-Iodo-2-hydroxy-3,4-dimethoxyphenyl) ethanone (3a).
To a solution of 3,4-dimethoxy-2-hydroxyacetophenone (0.855 g,
4.36 mmol) in acetonitrile (10 mL) was added p-toluenesulphonic
acid (0.750 g, 4.36 mmol) and the mixture stirred for 15 min. N-
Iodosuccinimide (0.980 g, 4.36 mmol) was added and the mixture
stirred for 40 h at room temperature. The reactionwas diluted with
dichloromethane and washed with aq. Na2S2O4, aq. NaHCO3 and
water. The combined organic layers were dried over anhydrous
magnesium sulphate and concentrated under vacuum to give the
crude product. Purification by flash chromatography
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white solid. (Yield: 0.955 g, 2.97 mmol, 68%). 1H NMR (CDCl3,
400 MHz, 20 C): d ¼ 12.58 (s, 1H, OH), 7.90 (s, 1H, ArH), 4.03 (s, 3H,
OCH3), 3.90 (s, 3H, OCH3), 2.59 (s, 3H, COCH3).13C NMR (CDCl3,
100 MHz, 20 C): d ¼ 202.7, 158.3, 157.8, 140.7, 134.9, 118.6, 78.2,
61.1, 60.9, 26.7. ESMS calcd for C10H11INaO4 [MþNa]þ: 344.9594,
found 344.9597. IR: n ¼ 2938, 1637, 1445, 1409, 1358, 1313, 1254,
1069, 1019, 753 cm1.
4 .1. 2 . 2 . 6 - A c e t y l - 4 - i o d o - 2 , 3 - d im e t h o x y p h e n y l - 3 , 4 -
dimethoxybenzoate (3b). To a solution of 1-(5-Iodo-2-hydroxy-3,4-
dimethoxyphenyl) ethanone (0.975 g, 3.027 mmol) in anhydrous
pyridine (5 mL) under argon, was added 3,4-dimethoxybenzoyl
chloride (1.82 g, 9.08 mmol) over a period of 15 min. The mixture
was stirred for 2 h at room temperature and then acidified with 2 N
HCl, extracted with ethyl acetate and washed with water. The
combined organic layers were dried over anhydrous magnesium
sulphate and concentrated under vacuum to give the crude prod-
uct. Purification by flash chromatography (30% ethyl acetate in
hexane) afforded the analytically pure product as a white solid.
(Yield: 1.40 g, 2.88 mmol, 95%). 1H NMR (CD2Cl2, 500 MHz, 20 C):
d ¼ 8.04 (s, 1H, ArH), 7.86 (dd, 1H, J ¼ 8.5, 2.0 Hz, ArH), 7.65 (d, 1H,
J¼ 2.0 Hz, ArH), 7.00 (d, 1H, J¼ 8.6 Hz, ArH), 3.95 (s, 3H, OCH3), 3.94
(s, 3H, OCH3), 3.91 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 2.47 (s, 3H,
COCH3). 13C NMR (CD2Cl2, 125 MHz, 20 C): d ¼ 195.4, 164.5, 157.4,
154.7, 149.7, 146.2, 145.8, 134.5, 130.1, 125.2, 121.4, 113.1, 111.3, 88.9,
61.6, 61.3, 56.6, 56.5, 30.4. ESMS calcd for C19H19INaO7 [MþNa]þ:
509.0068, found 509.0067. IR: n ¼ 2941, 1734, 1687, 1598, 1516,
1452, 1401, 1355, 1272, 1209, 1172, 1135, 1076, 1021, 752 cm1.
4.1.2.3. 1-(5-Iodo-2-hydroxy-3,4-dimethoxyphenyl)-3-(3,4-
dimethoxyphenyl)-1,3-propanedione (3c). To a solution of 6-acetyl-
4-iodo-2,3-dimethoxyphenyl-3,4-dimethoxybenzoate (1.18 g,
2.44 mmol) in anhydrous pyridine (5 mL), stirred at 50 C,
powdered potassium hydroxide (0.209 g, 3.73 mmol) was added.
After 1 h, the reaction mixture was cooled, acidified with 2 N HCl,
extracted with ethyl acetate and washed with water. The combined
organic layers were dried over anhydrous magnesium sulphate and
concentrated under vacuum to give the crude product. Purification
by flash chromatography (30% ethyl acetate in hexane) afforded the
analytically pure product as a yellow solid. NMR analysis in CD2Cl2
identified isomers in a 4:1 equilibrium of keto enol:1,3-diketone.
(Yield: 1.04 g, 2.14 mmol, 88%). 1H NMR (CD2Cl2, 500 MHz, 20 C):
d ¼ 15.67 (s, 0.8H, COCHCOH0), 12.41 (s, 0.8H, OH0), 12.25 (s, 0.2H,
OH), 7.95 (s, 1H, ArH), 7.60 (m, 1H, ArH), 7.51 (d, 0.2H, J ¼ 1.9 Hz,
ArH), 7.45 (d, 0.8H, J ¼ 2.2 Hz, ArH0) 6.95 (d, 0.8H, J ¼ 8.5 Hz, ArH0),
6.93 (d, 0.2H, J ¼ 8.5 Hz, ArH), 6.66 (s, 0.8H, COCH0COH), 4.54 (s,
0.4H, COCH2CO), 4.02 (s, 0.6H, OCH3), 4.00 (s, 2.4H, OCH03), 3.92 (s,
2.4H, OCH03), 3.917 (s, 2.4H, H OCH03), 3.914 (s, 0.6H, OCH3), 3.90 (s,
2.4H, OCH03), 3.89 (s, 0.6H, OCH3), 3.87 (s, 0.6H, OCH3). 13C NMR
(CD2Cl2, 125 MHz, 20 C): d ¼ 199.7, 193.2, 192.2, 178.8, 159.4, 158.8,
157.8,154.9,154.0,149.9,149.8,141.6,141.1,135.9,133.0,126.7,126.2,
124.3, 121.7, 119.0, 118.4, 111.5, 111.0, 110.8, 110.2, 91.8, 79.11, 79.07,
61.7, 61.6, 61.4, 61.3, 56.60, 56.56, 56.5, 56.4, 50.1. ESMS calcd for
C19H19INaO7 [MþNa]þ: 509.0068, found 509.0073. IR: n ¼ 2936,
1597, 1574, 1513, 1446, 1404, 1323, 1241, 1143, 1020, 754 cm1.
4.1.2.4. 3-Iodo-2-(3,4-dimethoxyphenyl)-7,8-dimethoxy-4H-chro-
men-4-one (3d). A suspension of 1-(5-Iodo-2-hydroxy-3,4-
dimethoxyphenyl)-3-(3,4-dimethoxyphenyl)-1,3-propanedione
(0.850 g, 1.75 mmol) and sodium acetate (1.70 g, 2.07 mmol) in
glacial acetic acid (10 mL) was refluxed for 2 h. After cooling, the
suspension was concentrated to minimum volume under reduced
pressure, extracted with ethyl acetate and washed with aq. NaHCO3
and water. The combined organic layers were dried over anhydrousmagnesium sulphate and concentrated under vacuum to give the
product as a white solid (Yield: 0.583 g, 1.25 mmol, 71%). 1H NMR
(CDCl3, 500MHz, 20 C): d¼ 8.11 (s, 1H, ArH-5), 7.67 (dd,1H, J¼ 8.5,
2.2 Hz, ArH-20), 7.56 (d, J¼ 2.2 Hz,1H, ArH-60), 7.16 (d,1H, J¼ 8.7 Hz,
ArH-30), 7.04 (s, 1H, ArH-3), 4.06 (s, 3H, OCH3), 3.98 (s, 3H,OCH3),
3.88 (s, 3H, OCH3), 3.86 (s, 3H, OCH3). 13C NMR (CDCl3, 125 MHz,
20 C): d¼ 175.3, 162.5, 155.5, 152.0, 150.5, 149.0, 140.9, 128.4, 123.1,
121.8, 119.7, 111.8, 109.1, 105.6, 89.0, 61.9, 61.2, 55.72, 55.66. ESMS
calcd for C19H17INaO6 [MþNa]þ: 490.9962, found 490.9966. IR:
n ¼ 1650, 1515, 1429, 1363, 1328, 1272, 1259, 1224, 1144, 1077, 1026,
730 cm1. HPLC (method B): Rt ¼ 13.48 min.
4.1.2.5. 3-Iodo-2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-4H-chro-
men-4-one (3). To a portion of 3-iodo-2-(3,4-dimethoxyphenyl)-
7,8-dimethoxy-4H-chromen-4-one (0.500 g, 1.07 mmol) dissolved
in anhydrous dichloromethane (20 mL) and cooled to 0 C, was
added slowly a 1 M solution of BBr3 in dichloromethane (10.7 mL,
10.7 mmol). The solution was stirred at room temperature for 12 h
and then diluted with iced water and the pH adjusted to 6 with aq.
NaHCO3. The mixture was extracted with ethyl acetate, and the
organic layer separated and washed with water and brine. The
combined organic layers were dried over anhydrous magnesium
sulphate and concentrated under vacuum to afford the analytically
pure product as a yellow solid. (Yield: 0.183 g, 0.444 mmol, 42%). 1H
NMR (d6-DMSO, 500 MHz, 20 C): d ¼ 10.43 (br. s, 4H, COH), 7.84 (s,
1H, ArH-5), 7.55 (m, 2H, ArH-20 þ 60), 6.90 (d,1H, J¼ 8.8 Hz, ArH-30),
6.61 (s, 1H, ArH-3). 13C NMR (d6-DMSO, 125 MHz, 20 C): d ¼ 175.4,
163.0,150.4,149.3,146.9,145.6,132.6,124.3,122.1,119.2,118.3,115.7,
113.9, 104.1, 83.1. ESMS calcd for C15H16IO6 [M  H]-: 410.9371,
found 410.9373. IR: n ¼ 1615, 1593, 1534, 1463, 1403, 1286, 1196,
1171, 1126, 1032 cm1. HPLC (method B): Rt ¼ 8.01 min. Elemental
analysis for C15H9IO6, calc: C 43.7%, H 2.2%, found: C 43.8%, H 2.4%.
4.1.2.6. 3-Iodo-2-(3,4-diacetoxyphenyl)-7,8-diacetoxy-4H-chromen-
4-one (3f). To a solution of 3-iodo-2-(3,4-dihydroxyphenyl)-7,8-
dihydroxy-4H-chromen-4-one (0.150 g, 0.364 mmol) in degassed
anhydrous pyridine (5.00mL)was added acetic anhydride (5.00mL)
and the reaction stirred at 45 C for 20 h. The solution was then
dilutedwith icedwater and stirred for a further 1 h at 0 C. Thewhite
precipitate formed was collected under vacuum filtration, washed
with ice cold water and further dried under high vacuum, before
purification by flash chromatography (10% ethyl acetate in
dichloromethane) afforded the analytically pure product as a white
solid. (Yield: 0.142g, 0.245mmol, 67%).1HNMR (d6-DMSO, 500MHz,
20 C): d ¼ 8.37 (s, 1H, ArH-5), 7.91 (ap. dq, J ¼ 4.6, 2.3 Hz, 2H, ArH-
20 þ 60), 7.52 (d, 1H, ArH-30), 7.16 (s, 1H, ArH-3), 2.51 (s, 3H, COCH3),
2.46 (s, 3H, COCH3), 2.332 (s, 3H, COCH3), 2.330 (s, 3H, COCH3). 13C
NMR (d6-DMSO,125MHz, 20 C): d¼ 174.8,168.2,168.0,167.3,167.1,
161.0, 148.5, 147.3, 144.9, 142.5, 132.1, 131.3, 129.0, 124.78, 124.68,
123.4,121.8,107.9, 89.2, 20.5, 20.4,19.8. ESMS calcd for C23H17INaO10
[MþNa]þ: 602.9759, found 602.9768. IR: n¼ 1779, 1654, 1428, 1361,
1196, 1119, 1074, 1018 cm1. HPLC (method B): Rt ¼ 12.58 min.
4.1.2.7. 2-(3,4-Diacetoxyphenyl)-7,8-diacetoxy-6-(trimethylstannyl)-
4H-chromen-4-one (3g). To a solution of 3-iodo-2-(3,4-
diacetoxyphenyl)-7,8-diacetoxy-4H-chromen-4-one (0.100 g,
0.172 mmol) in degassed anhydrous 1,4-dioxane (3.00 mL) was
added hexamethyldistannane (0.141 g, 0.090 mL, 0.431 mmol) and
bis-(triphenylphosphine)-palladium(II)-dichloride (1.21 mg,
1.72 mmol), and the solution stirred at 60 C for 90min under argon.
The solution was cooled to room temperature and filtered through
a plug of celite with dichloromethane washing. The solvent was
removed in vacuo and purification by flash chromatography on
neutral silica (10% ethyl acetate in dichloromethane) afforded the
analytically pure product as a white solid. (Yield: 61.7 mg,
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(84%), with Sn satellites (J2Sn-H ¼ 42 and 44 Hz (16%)), 1H, ArH-5),
7.70 (dd, J ¼ 8.5, 2.2 Hz, 1H, ArH-20), 7.67 (d, J ¼ 2.2 Hz, 1H, ArH-60),
7.36 (d, J ¼ 8.5 Hz, 1H, ArH-30), 6.72 (s, 1H, ArH-3), 2.41 (s, 3H,
COCH3), 2.35 (s, 3H, COCH3), 2.32 (s, 3H, COCH3), 2.32 (s, 3H,
COCH3), 0.38 (s (84%), with Sn satellites (J2Sn-H ¼ 55 and 57 Hz
(16%)), 9H, Sn(CH3)3). 13C NMR (CD2Cl2, 125 MHz, 20 C): d ¼ 177.3,
168.5, 168.4, 168.3, 167.6, 162.0, 151.6, 150.2, 145.3, 143.3, 134.3,
131.8, 130.8, 130.7, 124.94, 124.86, 123.1, 122.2, 109.1, 21.04, 21.02,
20.97, 20.7, -8.6 (with Sn satellites; 7.1, 7.2, 10.0, 10.1). ESMS
calcd for C26H26NaO10Sn [MþNa]þ: 641.0445, found 641.0434. IR:
n ¼ 1776, 1650, 1434, 1357, 1195, 1158, 1119, 1072, 1014 cm1. HPLC
(method B): Rt ¼ 14.01 min.
4.1.3. I-MST-312 compound data
4.1.3.1. N,N0-(5-Iodo-1,3-phenylene)bis(2,3-dimethoxybenzamide).
To a solution of 2,3-dimethoxybenzoic acid (0.804 g, 4.40 mmol) in
anhydrous dichloromethane (20 mL) under argon, was added 25 mL
anhydrous dimethylformamide. The solution was cooled to 0 C
and oxalyl chloride (740 mL,1.11 g, 8.80mmol) added dropwise with
stirring. The solution was allowed to warm to room temperature
and stirred for a further 24 h. The solvent was removed under
reduced pressure and the residue washed three times with fresh
anhydrous dichloromethane, followed by drying under vacuum for
1 h to yield the crude 2,3-5-dimethoxybenzoyl chloride. To a so-
lution of 1-iodo-3,5-diaminobenzene (0.468 g, 2.00 mmol) in
anhydrous pyridine (10 mL) under argon, was added dropwise the
crude 2,3-dimethoxybenzoyl chloride in dichloromethane (5 mL)
over a period of 15 min. The mixture was then stirred for 2 h at
room temperature, and then acidified with 2 N HCl, extracted with
ethyl acetate and washed with water. The combined organic layers
were dried over anhydrous magnesium sulphate and concentrated
under vacuum to give the crude product. Purification by flash
chromatography (30% ethyl acetate in hexane) afforded the
analytically pure product. (Yield: 0.922 g, 1.64 mmol, 82%). 1H NMR
(CD2Cl2, 400 MHz, 20 C): d ¼ 10.07 (s, 2H, NH), 8.12 (t, J ¼ 1.8 Hz,
1H, ArH), 7.88 (d, J ¼ 2.0 Hz, 2H, ArH), 7.72 (dd, J ¼ 8.1, 1.5 Hz, 2H,
ArH), 7.21 (t, J ¼ 7.9 Hz, 2H, ArH), 7.14 (dd, J ¼ 8.2, 1.6 Hz, 2H, ArH),
4.01 (s, 6H, 2  OCH3), 3.92 (s, 6H, 2  OCH3).13C NMR (CD2Cl2,
100 MHz, 20 C): d ¼ 163.5, 153.3, 148.0, 140.6, 126.8, 125.1, 124.8,
123.1, 116.7, 111.5, 94.3, 62.2, 56.7. ESMS calcd for C24H23IN2NaO6
[MþNa]þ: 585.0493, found 585.0496. HPLC: Rt ¼ 14.82 min
(Method B). IR: n ¼ 3319, 1674, 1593, 1578, 1530, 1471, 1435, 1315,
1264, 1057, 984, 741 cm1.
4.1.3.2. N,N0-(5-Iodo-1,3-phenylene)bis(2,3-dihydroxybenzamide).
To a solution of N,N0-(5-iodo-1,3-phenylene)bis(2,3-
dimethoxybenzamide) (0.100 g, 0.178 mmol) in anhydrous
dichloromethane (15 mL), cooled to 0 C, was added, dropwise, a
1 M solution of BBr3 in dichloromethane (1.78 mL, 1.78 mmol). The
reaction was stirred for 12 h at room temperature and then diluted
with iced water (100mL). The pH of the suspensionwas adjusted to
6 with 5% NaHCO3, extracted with ethyl acetate and washed with
water and brine. The combined organic layers were dried over
anhydrous magnesium sulphate and concentrated under vacuum
to afford the analytically pure product as a yellow solid. (Yield:
41.7 mg, 82.3 mmol, 46%). 1H NMR (d6-DMSO, 400 MHz, 20 C):
d ¼ 11.37 (s, 2H, OH), 10.43 (s, 2H, OH), 9.50 (br. s., 2H, NH), 8.13 (t,
J ¼ 1.8 Hz, 1H, ArH), 7.94 (d, J ¼ 1.8 Hz, 2H, ArH), 7.41 (dd, J ¼ 8.0,
1.1 Hz, 2H, ArH), 6.99 (dd, J¼ 7.8, 1.1 Hz, 2H, ArH), 6.78 (t, J¼ 8.0 Hz,
2H, ArH). 13C NMR (d6-DMSO, 100 MHz, 20 C): d ¼ 168.4, 148.8,
147.1, 140.6, 125.7, 119.9, 119.5, 118.3, 113.5, 94.9. ESMS calcd for
C20H15IN2NaO6 [MþNa]þ: 528.9867, found 528.9856. HPLC:
Rt ¼ 11.49 min (Method B). IR: n ¼ 3360, 1648, 1589, 1533, 1462,
1436, 1333, 1256, 1184, 849, 730 cm1.4.1.3.3. N,N 0-(5-(Trimethylstannyl)-1,3-phenylene)bis(2,3-
diacetoxybenzamide). To a solution of 2,3-bis(acetyloxy)benzoic
acid (0.263 g, 1.1 mmol) in anhydrous dichloromethane (20 mL)
under argon, was added 25 mL anhydrous dimethylformamide. The
solution was cooled to 0 C and oxalyl chloride (185 mL, 0.278 g,
2.2 mmol) added dropwise with stirring. The solution was allowed
to warm to room temperature and stirred for a further 24 h. The
solvent was removed under reduced pressure and the residue
washed three times with fresh anhydrous dichloromethane,
followed by drying under vacuum for 1 h to yield the crude 2,3-
bis(acetyloxy)benzoyl chloride. To a solution of 1-iodo-3,5-
diaminobenzene (0.117 g, 0.50 mmol) in anhydrous pyridine
(10 mL) under argon, was added dropwise the crude 2,3- bis(ace-
tyloxy)benzoyl chloride in dichloromethane (5mL) over a period of
15 min. The mixture was then stirred for 2 h at room temperature,
and then acidified with 2 N HCl, extracted with ethyl acetate and
washed with water. The combined organic layers were dried over
anhydrous magnesium sulphate and concentrated under vacuum
to give the crude product. The crude product was semi-purified by
flash chromatography (30% ethyl acetate in hexane) to afford a
mixture of products. To a solution of this crudemixture in degassed
anhydrous 1,4-dioxane (5 mL) is added hexamethyldistannane
(184 mL, 292 mg, 0.891 mmol) and bis-(triphenylphosphine)-pal-
ladium(II)-dichloride (2.60 mg, 3.71 mmol), and the solution stirred
at 75 C for 12 h. The solution was cooled to room temperature,
filtered through a plug of celite and washed with dichloromethane.
The solvent was removed in vacuo and purification by flash chro-
matography (10% ethyl acetate in dichloromethane) afforded the
analytically pure product. (Yield: 0.092 g, 0.13 mmol, 26%). 1H NMR
(CD2Cl2, 500 MHz, 20 C): d¼ 8.03 (s, 3H, 3 ArH), 7.68 (dd, J¼ 7.6,
1.6 Hz, 2H, ArH), 7.43 (d (84%), J ¼ 1.6 Hz with Sn satellites (J2Sn-
H ¼ 54 and 56 Hz (16%), 2H, ArH), 7.39 (t, J ¼ 7.8 Hz, 2H, ArH), 7.36
(dd, J ¼ 1.8 Hz, 2H, ArH), 2.32 (s, 6H, COCH3), 2.31 (s, 6H, COCH3),
0.33 (s (84%) with Sn satellites (J2Sn-H ¼ 54 and 56 Hz (16%)), 9H,
Sn(CH3)3).13C NMR (CD2Cl2, 125 MHz, 20 C): d ¼ 168.8, 168.6,
163.4, 145.4, 143.7, 140.6, 138.5, 131.3, 127.4, 127.2, 126.8, 123.6,
112.3, 21.0, 20.9, -9.2 (Sn(CH3)3). ESMS calcd for C31H32N2NaO10Sn
[MþNa]þ: 735.0971, found 735.0982. IR: n¼ 3341, 1773,1676, 1590,
1535, 1460, 1425, 1371, 1203, 1018 cm1. HPLC: Rt ¼ 12.46 min
(Method B).
4.2. Radiolabeling
4.2.1. I-BIBR-1532 (1)
To a solution of the trimethyltin analogue of BIBR-1532 (1d),
(20 mg, 0.040 mmol) in ethanol (20 mL), was added [123I]-NaI
(150 MBq, 5 mL) and Chloramine T trihydrate (20 mL, 1 mg/mL so-
lution in water). After 15 min at room temperature, Na2S2O5 (1 mg,
6.32 mmol in 20 mL H2O), NaHCO3 (2 mg, 23.81 mmol in 20 mL H2O),
and 350 mL of HPLC mobile phase were added. The resulting
mixture was purified by semi-preparative HPLC (Method A). The
radiolabeled compound (retention time Rt: 9.89min) was collected,
loaded onto a pre-conditioned C18 Seppak cartridge (pre-eluted
with 2 mL ethanol followed with 5 mL H2O) washed with 5 ml H2O
until pH of eluent reached pH 7. [123I]-(1) was then eluted with
0.5 mL methanol, collected and concentrated to dryness under a
stream of nitrogen gas, and resuspended in DMSO (4 mL). The
radioiodinated tracer was then formulated in 100 mL PBS or DME
medium (final DMSO volume 4%) for in vitro evaluation. End of
synthesis radiochemical yields, purities and specific activity mea-
surements, represent the mean of at least five independent mea-
surements (±SD). For HPLC determination of the specific activity of
radiolabeled compound a calibration curve (linear regression
analysis of mass from solutions of known compound concentration
versus peak area of UV absorption) was plotted.
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To a solution of the trimethyltin flavonoid analogue (3g) (20 mg,
0.049 mmol) in ethanol (20 mL), was added [123I]-NaI (150MBq, 5 mL)
and H2O2:acetic acid (1:3) (20 mL). After 15 min at room tempera-
ture, Na2S2O5 (1 mg, 6.32 mmol in 20 mL H2O), NaHCO3 (2 mg,
23.81 mmol in 20 mL H2O), and 3.00 mL of deionised H2O were
added. The solution was loaded onto a pre-conditioned C18 Seppak
cartridge (pre-eluted with 2 mL ethanol followed with 5 mL H2O)
washed with 5 mL H2O, eluted with 2 mL methanol, collected and
concentrated to minimal volume under a stream of nitrogen gas.
3 M HCl (50 mL) was added to the radiolabeled species in a sealed
glass vial and heated at 80 C for 30min. The reactionwas cooled to
room temperature and subsequently purified by semipreparative
HPLC (Method B). The radiolabeled compound (retention time Rt:
8.01 min) was collected, loaded onto a pre-conditioned C18 Seppak
cartridge (pre-eluted with 2 mL ethanol followed with 5 mL H2O)
washedwith 5ml H2O until pH of eluent reached pH 7. The [123I]-(3)
was then eluted with 2 mLmethanol, collected and concentrated to
dryness under a stream of nitrogen gas, and resuspended in DMSO
(5 mL). The radioiodinated tracer was then formulated in 100 mL PBS
or DME medium (final DMSO volume 5%) for in vitro evaluation.
Flavonoids (4g and 5g) were radiolabeled in an identical manner.
4.2.3. I-MST-312: (6f)
I-MST-312 (retention time Rt: 11.35 min) was radiolabeled in an
identical manner to the flavonoid analogues.
4.3. Octanol/PBS distribution coefficient (LogD) and octanol/water
partition coefficient (LogP)
The distribution coefficients (log D) and partition coefficients
(log P) of the radiolabeled compounds were determined by addi-
tion of a sample of the HPLC-purified radiolabeled compound
(500 kBq) to equal amounts of water or PBS (pH 7.4) and octanol
(500 ml each). The vials were vortexed vigorously for 1 min. To
achieve phase separation, the vials were centrifuged (2500 rpm) for
6 min. The radioactivity concentrationwas determined in a defined
volume of each layer measured in a g-counter. The distribution
coefficient was expressed as the ratio of counts per minute (cpm)
measured in the octanol phase to the cpm measured in either the
water or PBS phase. The results represent the mean of three inde-
pendent measurements (±SD), each performed in quintuplicate.
4.4. Telomerase Repeat Amplification Protocol (TRAP) assay
The TRAP assay was set-up as recommended, with the following
modifications: the PCR cycle was optimized to 30 C, 30 min; fol-
lowed by 36 cycles of 94 C/30 s; 53.5 C/30 s; 72 C/60 s; and a final
extension step of 72 C/3 min. PCR reactions contained two units of
Jumpstart-Taq, 2 mL of CHAPS-extracted cell lysate (see ESI for lysate
preparation) containing 200 ng of protein, and 5x Reaction buffer;
and were made-up to 50 mL with nuclease-free water. TSR8 tem-
plate positive (0.2 amoles) and heat-inactivated-lysate (80 C,
10 min) negative controls were included in each experiment. For
inhibition experiments, inhibitor or control was added to a total
volume of 55.5 mL, to the telomerase extension step (30 C, 30 min).
Samples were analysed by addition of 40 mL of each reaction to
160 mL of read buffer in 96-well format using a fluorescence plate
reader. Signals attributed to the addition of telomeric repeats to a
substrate primer (TS), and so telomerase activity, are represented
by fluorescein emission following excitation (485/535 nm). The
assay also includes an internal PCR control template and primer
labeled with sulforhodamine (585/620 nm). Data processing in-
volves subtraction of background signals, obtained from extract-
free and Taq polymerase-free controls, producing telomerase(DFl) and internal control (DSulf) signals respectively. Telomerase
signals are then normalized to internal PCR control (DFl/DSulf) to
allow direct comparison of relative activities. The determined
telomerase activity was normalized to untreated control. Data were
fitted using fixed-slope non-linear regression and compared using
an exact-sum-of-squares F-test in GraphPad Prism 5.0.
4.5. Complex stability
The stability of radiolabeled molecules was determined in PBS,
and in serum containing medium. HPLC purified radiolabeled
agents (50 MBq, 25 mL) were mixed with either 475 mL of PBS or
475 mL of medium and incubated at 37 C. Aliquots of the PBS
samples were taken for analysis at defined time points after incu-
bation (0, 1, 4, 8 and 24 h) and analysed directly by radio-HPLC.
Aliquots (50 mL) of the medium samples were taken for analysis
at defined time points after incubation (0, 1, 4, 8 and 24 h), diluted
with 450 mL MeOH to precipitate out proteins and the remaining
solution analysed by radio-HPLC.
4.6. Internalization assay
Cells were harvested into an eppendorf at a density of 105 cells
in 250 mL of medium. Cells were treated for the indicated time in a
total volume of 500 mL of medium, with 0.2 MBq of compound. Cell
treatment was staggered to allow time-points to be processed
together. Following incubation, cells were pelleted by centrifuga-
tion (500  g, 5 min) and the medium was aspirated and retained.
Cells were then washed twice with 500 mL and 250 mL PBS, and the
washes combined with the medium to constitute the free-fraction.
Free-fractions were diluted 10-fold to facilitate counting in a g-
counter. Cells were re-pelleted and cell membranes washed using
500 mL glycine (pH 2.5) and incubated at 4 C for 6 min before
washing with 500 mL PBS. Following re-pelleting, internalized and
nuclear fractions were isolated using a Thermo Scientific Subcel-
lular Protein Fractionation Kit for Cultured Cells. Fractions were
counted in a Wizard Automatic gamma-counter (Perkin-Elmer
2480). Where appropriate data were fitted with a two-phase as-
sociation model and compared using an exact-sum-of-squares F-
test in GraphPad Prism 5.0.
4.7. Clonogenic assay
Cells were harvested and added to an eppendorf at a density of
105 cells in 250 mL of medium. Compound was added to the desired
concentration or activity to a total volume of 500 mL of medium.
Solvent or cold compound (to a concentration equivalent to the
highest activity) treated cells were included as a control. Cells were
then incubated for 24 h before plating in six-well plates at a density
sufficient to give >50 colonies for counting. Untreated cells were
typically seeded at 750 cells/well. Colonies were grown for >7 days,
washed in PBS and stained with 1% methylene blue (in 50%
methanol). Excess stain was washed-off with water. Colonies con-
taining >50 cells were counted. The surviving fraction (SF) was
calculated using the plating efficiency (PE) of untreated cells.
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